UCEA - Capital Partners

We are thrilled to announce the first speaker Micreos at our recent Zurich event. Founded in 2005, Micreos is a clinical-stage biotech company specializing in the discovery and development of recombinant proteins for chronic dermatology and oncology conditions. The company aims to create medical solutions that selectively target harmful bacteria while preserving the beneficial microbiome. Micreos focuses on unmet medical needs, such as atopic dermatitis, a chronic relapsing skin disease affecting 38 million patients. The market for atopic dermatitis was valued at $11.4 billion in 2021 and is projected to reach $24.4 billion by 2030. Our Family Office is taking a closer look at their research to take a view on this opportunity. #UCEACapital #investing #familyoffices #Zurich #biotech #oncology #dermatitis #recombinantprotiens 

We are excited to share a preview of our recent event in Zurich, hosted at the Zurich Marriott Hotel. The event showcased an engaging lineup of speakers who offered their expertise and insights on diverse topics in Healthcare, Healthtech, and Pharmaceuticals. Each presenter delivered unique perspectives, making the occasion truly memorable. Stay tuned for more thrilling highlights! #UCEACapital #investing #familyoffices #Zurich #Healthcare #HealthTech #Pharma 

We are thrilled to have one of our portfolio company, Chakra Growth Capital as the closing speaker of our recent Dubai Family Event. Based in Silicon Valley and Europe, with roots in India, Chakra brings valuable operational and strategic experience to help early-stage startups grow. Rather than prioritizing investments maximizing financial returns alone, Chakra partners with Indian tech enterprises striving for positive local impact alongside global influence. Their patient funding model empowers companies to benefit society and the planet while still achieving profitability. Supported by over 200 incubators with government and academic backing, and enriched by the presence of large international VCs, the Indian startup culture has matured and is market ready. #UCEACapital #investing #familyoffices #Dubai #growthfund #cleantech #Indianenterprises #investenergy 

We are thrilled to announce the closing speaker at our recent Dubai event VIIHEALTH, INC.. VIIHEALTH specializes in healthcare omnichannel solutions, providing a customer engagement platform that empowers life sciences. Their workspace enhances, tailors, and expands AI-driven interactions with customers, allowing family members access to personal health data. The global Digital Therapeutics and Software as a Medical Device (SaMD) market is projected to exceed $86.4 billion by 2030, underscoring the growing importance of digital health technologies in life sciences and indicating significant market growth ahead. #UCEACapital #investing #familyoffices #Dubai #heathcare #healthtech #digitaltherapeutics 

We are thrilled to announce the fourth speaker at our recent Dubai event LifeQ, Inc. LifeQ Global Limited, a US-based digital health company, specializes in developing clinically validated software solutions for comprehensive health monitoring via everyday wearables. By focusing on preventative healthcare, LifeQ provides users with personalized health insights and guidance. The market for wearable health monitoring, where LifeQ operates, was valued at $59 billion in 2022 and is expected to grow at a CAGR of 28.6%, reaching $430 billion by 2030. Our Family Office is taking a closer look at their technology to take a view on this opportunity. #UCEACapital #investing #familyoffices #Dubai #healthtech #wearables #healthcare #innovation 

We are thrilled to announce the second speaker at our recent Dubai event EpiOn Epion, a US-based HealthTech company, provides minimally invasive solutions for ectatic corneal diseases. EpiSmart, Epion's groundbreaking treatment, offers a novel corneal cross-linking solution for conditions like keratoconus. This treatment uses a proprietary blend of riboflavin and sodium iodide for cross-linking while preserving the corneal epithelium (epi-on). The global market for corneal cross-linking is currently valued at approximately $500 million annually, with Europe and the Asia-Pacific regions expected to experience accelerated growth rates in the future. Our Family Office is taking a closer look at their technology to take a view on this opportunity. #UCEACapital #investing #familyoffices #Dubai #cornealhealth #optics #healthcare #Epion #HealthTech 

We are thrilled to announce the fourth speaker at our recent Dubai event Graphiant. Graphiant has developed a groundbreaking internet connectivity service using a unique metadata protocol, transforming the internet into a customizable, secure network. The core of Graphiant's framework is a customizable metadata plane, enabling virtualized overlay networking, automated services, and reliable internet connectivity. With a comprehensive patent portfolio protecting its foundational system architecture and innovative technologies, Graphiant is targeting a significant total addressable market of $20 billion, encompassing service providers and government agencies. Our Family Office is taking a closer look at their technology to take a view on this opportunity. #UCEACapital #investing #familyoffices #Dubai #tech #innovation #metadata #network #web2 

We are thrilled to announce the fourth speaker at our recent Dubai event MyLand Agriculture, A Soil Health Company. Founded in 2017, MyLand is a pioneering company in regenerative agriculture, tackling the critical issue of soil degradation. MyLand’s innovative solution involves extracting native microorganisms from a farm’s soil, reproducing them on-site, and reintroducing them through existing irrigation systems. Headquartered in Phoenix, Arizona, with operations across multiple U.S. states, MyLand aims to sustainably improve soil health and enhance agricultural productivity. The $150 billion global soil health market is fueled by the need for sustainable agriculture, food security, and climate change mitigation. Our Family Office is taking a closer look at their technology to take a view on this opportunity. #UCEACapital #investing #familyoffices #Dubai #regenerativeagriculture #innovation #irrigation #sustainability  

We are thrilled to announce the third speaker at our recent Dubai event Kobo360. Kobo360 was established in 2018 to address inefficiencies in Africa’s supply chain. The company has created a platform that seamlessly connects manufacturers and cargo owners with truck operators, facilitating the movement of goods across the continent. The increasing demand for high-quality logistics space, driven by the growth of Africa's middle class and the expansion of consumer markets, is fueling retailers and consumer goods manufacturers to enhance their distribution networks and supply chains across Africa. Our Family Office is taking a closer look at their strategies to take a view on this opportunity. #UCEACapital #investing #familyoffices #Dubai #supplychain #distribution #africa #investafrica 

We are thrilled to announce the second speaker at our recent Dubai event CNS Pharmaceuticals, Inc.. CNS Pharmaceuticals, founded in 2017 and based in Houston, Texas, is a clinical-stage pharmaceutical company focused on developing anticancer drug candidates for treating primary and metastatic brain and central nervous system tumors. The global market for brain metastasis therapeutics, valued at $2.79 billion in 2022, is projected to grow at a compound annual growth rate of 10.2%, reaching $6.69 billion by 2031. CNS Pharmaceuticals is dedicated to advancing treatments for patients with primary or secondary brain cancers through the development and manufacture of novel drugs.   Our Family Office is taking a closer look at their research to take a view on this opportunity. #UCEACapital #investing #familyoffices #Dubai #pharma #tumor #therapeutics #braincancer